| scholarly article | Q13442814 |
| P50 | author | Michael T Lotze | Q89121415 |
| Steven Rosenberg | Q2347448 | ||
| P2093 | author name string | Gimbrone MA Jr | |
| Cotran RS | |||
| Pober JS | |||
| Springer TA | |||
| Gaspari AA | |||
| Wiebke EA | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| vascular leak syndrome | Q2511036 | ||
| P304 | page(s) | 1883-1888 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome | |
| P478 | volume | 140 |
| Q45156441 | Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. |
| Q41912528 | Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice |
| Q36056734 | CAMs and anti-CAMs. The clinical potential of cell adhesion molecules |
| Q40725559 | Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients. |
| Q43448304 | Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro |
| Q37593608 | Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models |
| Q39330984 | Delivering safer immunotherapies for cancer |
| Q68004793 | Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome |
| Q71689311 | Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro |
| Q45857564 | Effects of vaccinia virus-expressed interleukin 2 on the immune system of sublethally irradiated mice |
| Q48945662 | Evaled expression of ICAM-1 and its ligands in the rat spinal cord following lipopolysaccharide intraspinal injection |
| Q24796741 | Forecasting the cytokine storm following systemic interleukin (IL)-2 administration |
| Q37475949 | Functions of γC cytokines in immune homeostasis: current and potential clinical applications |
| Q24802736 | Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration |
| Q44622972 | Generalized inflammation during peritonitis evidenced by intracutaneous E-selectin expression |
| Q37935496 | Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations |
| Q46108125 | In vivo biology of recombinant interleukin-2 infusion in sheep: cardiopulmonary manifestations of an intravascular immune-inflammatory response |
| Q48362877 | In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. |
| Q72394548 | Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer |
| Q41583651 | Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems |
| Q42453362 | Intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) expression in human epiretinal membranes |
| Q35811710 | Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system |
| Q33774512 | Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. |
| Q50920911 | Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development. |
| Q70898869 | Intracerebral vascular occlusion in familial erythrophagocytic lymphohistiocytosis: a case report of two siblings |
| Q27027097 | Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy |
| Q44499384 | Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response |
| Q27692606 | NK cells in the tumor microenvironment |
| Q69609528 | Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice |
| Q55032798 | Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection of the killer cells with the gamma-interferon gene. |
| Q34245154 | Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma |
| Q48333773 | Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma |
| Q35992936 | The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. |
| Q72790073 | The immunobiological effects of interleukin-2 in vivo |
| Q35190753 | The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. |
| Q40931125 | The role of the immune system in anti-tumour responses. Potential for drug therapy |
| Q47389809 | Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy |
| Q46863834 | Therapy strategies for advanced renal cell carcinoma |
| Q36806259 | Vascular leak is a central feature in the pathogenesis of systemic sclerosis |
| Q37438906 | Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice |
| Q35819144 | Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology |
Search more.